By Brandon Newman, CEO of Xevant
Spread pricing by pharmacy benefit managers (PBMs) is often portrayed in a negative light due to its perceived impact on drug costs and pharmacy reimbursements. However, it’s essential to explore the nuances of this practice to understand its full scope and potential benefits. While the criticism of spread pricing is valid in certain contexts, there’s another side to this coin that deserves attention. It is critical to dive into the complexities of spread pricing in order to find a balanced perspective on its role in the pharmaceutical industry.
